Steven Farber, JD, PA-C
DownloadHi-Res Photo
About
Biography
Steven has been working with people living with HIV (PLWHIV) since 1982 in the Bronx where he worked with one of the first Methadone Maintenance Treatment Programs to offer primary care to HIV positive individuals with Opiate Use Disorder (OUD). Later in New Haven he continued his HIV work at Yale's Nathan Smith Clinic. In addition, he spent some time seeing patients at the Connecticut Department of Corrections. He left clinical practice briefly to work with Bristol Myers - Squibb. He then returned to HIV practice at the West Haven VA.
Appointments
Infectious Diseases
Clinical InstructorPrimary
Other Departments & Organizations
Education & Training
- JD
- University of Bridgeport (1991)
- BS
- Rutgers University (1980)
- PA
- Rutgers University (1980)
Research
Research at a Glance
Yale Co-Authors
Frequent collaborators of Steven Farber's published research.
Publications Timeline
A big-picture view of Steven Farber's research output by year.
Amy Justice, MD, PhD
Shaili Gupta, MBBS
5Publications
61Citations
Publications
2015
HIV+ patient on suppressive antiretroviral therapy with steroid injection-induced myopathy
Farber SJ, Sutton RE. HIV+ patient on suppressive antiretroviral therapy with steroid injection-induced myopathy. AIDS 2015, 29: 1422-1424. PMID: 26098599, DOI: 10.1097/qad.0000000000000738.Peer-Reviewed Original ResearchCitations
2013
A Study of Financial Incentives to Reduce Plasma HIV RNA Among Patients in Care
Farber S, Tate J, Frank C, Ardito D, Kozal M, Justice AC, Scott Braithwaite R. A Study of Financial Incentives to Reduce Plasma HIV RNA Among Patients in Care. AIDS And Behavior 2013, 17: 2293-2300. PMID: 23404097, PMCID: PMC3742414, DOI: 10.1007/s10461-013-0416-1.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsViral load suppressionFeasibility outcomesPatient acceptabilityPatient comprehensionPlasma HIV RNADetectable viral loadViral load testsSingle-site studyEligible patientsHIV careHIV RNAART adherenceViral loadHIV transmissionOwn controlPatientsPatient workflowFinancial incentivesOutcomesCareDownstream costsIncentive sizeBiological outcomesAcceptabilityClinic
2009
Development of an Electronic Medical Record-Based Clinical Decision Support Tool to Improve HIV Symptom Management
Nader CM, Tsevat J, Justice AC, Mrus JM, Levin F, Kozal MJ, Mattocks K, Farber S, Rogers M, Erdos J, Brandt C, Kudel I, Braithwaite R. Development of an Electronic Medical Record-Based Clinical Decision Support Tool to Improve HIV Symptom Management. AIDS Patient Care And STDs 2009, 23: 521-529. PMID: 19538046, PMCID: PMC3048777, DOI: 10.1089/apc.2008.0209.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsMeSH KeywordsAdultDecision Making, Computer-AssistedDecision Support Systems, ClinicalFemaleHIV InfectionsHumansMaleMedical Records Systems, ComputerizedMiddle AgedPatient SatisfactionPilot ProjectsPractice Guidelines as TopicPractice Patterns, Physicians'Severity of Illness IndexSurveys and QuestionnairesUnited StatesUnited States Department of Veterans AffairsConceptsClinical decision support toolVeterans Health Administration electronic medical recordsElectronic medical recordsSymptom managementMedical recordsProvider awarenessProgress notesClinical HIV careHIV symptom managementEMR notesHIV careHIV clinicClinical responseControl patientsHIV diseaseCommon symptomsPoint of careHIV symptomsProvider notesPatients' perceptionsIntervention groupIntervention periodCare plansPatientsSymptomsRaltegravir With Unboosted Atazanavir 300 mg Twice Daily in Antiretroviral Treatment-Experienced Participants
Gupta S, Lataillade M, Farber S, Kozal MJ. Raltegravir With Unboosted Atazanavir 300 mg Twice Daily in Antiretroviral Treatment-Experienced Participants. Journal Of The International Association Of Providers Of AIDS Care (JIAPAC) 2009, 8: 87-92. PMID: 19270153, DOI: 10.1177/1545109709332471.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsMean CD4 count increaseCD4 count increaseCombination of raltegravirTreatment-experienced patientsPotent antiretroviral activityCopies/mLProtease inhibitorsARV agentsUnboosted atazanavirHIV RNAImmunologic outcomesTwice DailyAntiretroviral treatmentARV therapyAntiretroviral agentsCase seriesHIV integrase inhibitorsTherapeutic failureAntiretroviral activityRaltegravirAtazanavirIntegrase inhibitorsAdverse effectsCells/Count increase
1998
Regression of HIV encephalopathy and basal ganglia signal intensity abnormality at MR imaging in patients with AIDS after the initiation of protease inhibitor therapy.
Filippi CG, Sze G, Farber SJ, Shahmanesh M, Selwyn PA. Regression of HIV encephalopathy and basal ganglia signal intensity abnormality at MR imaging in patients with AIDS after the initiation of protease inhibitor therapy. Radiology 1998, 206: 491-8. PMID: 9457204, DOI: 10.1148/radiology.206.2.9457204.Peer-Reviewed Original Research